Role of MAP kinase in tumor progression and invasion

Cancer and Metastasis Reviews

Volumn 22, Issue 4, 2003, Pages 395-403

  Reddy, Kaladhar B ^a   Nabha, Sanaa M ^a   Atanaskova, Natasha ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Invasion; MAPK; Metastasis; Migration; Proteinases

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

ANGIOGENESIS; APOPTOSIS; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

APOPTOSIS; CELL MOVEMENT; DISEASE PROGRESSION; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 0038048211     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023781114568     Document Type: Review

References (99)

1. Reddy KB, Krueger JS, Kondapaka SB, Diglio CA: Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 82: 268-273, 1999
2. Krueger JS, Keshamouni VG, Atanaskova N, Reddy KB: Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20: 4209-4218, 2001
3. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822, 1999
4. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483, 1997
5. Salh B, Marotta A, Matthewson C, Ahluwalia M, Flint J, Owen D, Pelech S: Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 19: 731-740, 1999
6. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U: Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 89: 384-388, 2000
7. Wilsbacher JL, Goldsmith EJ, Cobb MH: Phosphorylation of MAP kinases by MAP/ERK involves multiple regions of MAP kinases. J Biol Chem 274: 16988-16994, 1999
8. Ahn NG: The MAP kinase cascade. Discovery of a new signal transduction pathway. Mol Cell Biochem 127-128: 201-209, 1993
9. Widmann C, Gibson S, Jarpe MB, Johnson GL: Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143-180, 1999
10. Garrington TP, Johnson GL: Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11: 211-218, 1999
11. Lenormand P, Brondello JM, Brunet A, Pouyssegur J: Growth factor-induced p42/p44 MAPK nuclear translocation and retention requires both MAPK activation and neosynthesis of nuclear anchoring proteins. J Cell Biol 142: 625-633, 1998
12. Adachi M, Fukuda M, Nishida E: Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J Cell Biol 148: 849-856, 2000
13. Groom LA, Sneddon AA, Alessi DR, Dowd S, Keyse SM: Differential regulation of the MAP, SAP and RK/p38 kinases by Pystl, a novel cytosolic dual-specificity phosphatase. Embo J 15: 3621-3632, 1996
14. Chernoff J: Protein tyrosine phosphatases as negative regulators of mitogenic signaling. J Cell Physiol 180: 173-181, 1999
15. Zheng CF, Guan KL: Dephosphorylation and inactivation of the mitogen-activated protein kinase by a mitogen-induced Thr/Tyr protein phosphatase. J Biol Chem 268: 16116-16119, 1993
16. Chu Y, Solski PA, Khosravi-Far R, Der CJ, Kelly K: The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 271: 6497-6501, 1996
17. Gonzalez FA, Raden DL, Rigby MR, Davis RJ: Heterogeneous expression of four MAP kinase isoforms in human tissues. FEBS Lett 304: 170-178, 1992
18. Cheng M, Boulton TG, Cobb MH: ERK3 is a constitutively nuclear protein kinase. J Biol Chem 271: 8951-8958, 1996
19. Zhou G, Bao ZQ, Dixon JE: Components of a new human protein kinase signal transduction pathway. J Biol Chem 270: 12665-12669, 1995
20. Lee JD, Ulevitch RJ, Han J: Primary structure of BMK1: A new mammalian map kinase. Biochem Biophys Res Commun 213: 715-724, 1995
21. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 713-716, 1998
22. English JM, Pearson G, Hockenberry T, Shivakumar L, White MA, Cobb MH: Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J Biol Chem 274: 31588-31592, 1999
23. Abe MK, Kuo WL, Hershenson MB, Rosner MR: Extracellular signal-regulated kinase 7 (ERKT), a novel ERK with a C-terminal domain that regulates its activity, its cellular localization, and cell growth. Mol Cell Biol 19: 1301-1312, 1999
24. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22: 153-183, 2001
25. Pawson T, Scott JD: Signaling through scaffold, anchoring, and adaptor proteins. Science 278: 2075-2080, 1997
26. Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss A, Weber MJ: MP1: A MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 281: 1668-1671, 1998
27. Elion EA: Routing MAP kinase cascades. Science 281: 1625-1626, 1998
28. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ: A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277: 693-696, 1997
29. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ: A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281: 1671-1674, 1998
30. Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, Templeton DJ: Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372: 798-800, 1994
31. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121-125, 1990
32. Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 14: 455-463, 1992
33. Rochefort H, Capony F, Garcia M: Cathepsin D: A protease involved in breast cancer metastasis. Cancer Metastasis Rev 9: 321-331, 1990
34. Coutts AS, Murphy LC: Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 58: 4071-4074, 1998
35. McCawley LJ, Li S, Wattenberg EV, Hudson LG: Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 274: 4347-4353, 1999
36. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC: Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8: 1747-1753, 2002
37. Overall CM, Lopez-Otin C: Strategies for mmp inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672, 2002
38. Ree AH, Bjornland K, Brunner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O: Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis 16: 205-215, 1998
39. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D: Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 271: 10672-10680, 1996
40. Kondapaka SB, Fridman R, Reddy KB: Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 70: 722-726, 1997
41. Brogley MA, Cruz M, Cheung HS: Basic calcium phosphate crystal induction of collagenase 1 and stromelysin expression is dependent on a p42/44 mitogen-activated protein kinase signal transduction pathway. J Cell Physiol 180: 215-224, 1999
42. Mazumdar A, Adam L, Boyd D, Kumar R: Heregulin regulation of urokinase plasminogen activator and its receptor: Human breast epithelial cell invasion. Cancer Res 61: 400-405, 2001
43. Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D: Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20: 8066-8074, 2001
44. Vu TH, Werb Z: Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev 14: 2123-2133, 2000
45. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176, 2000
46. Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10: 415-433, 2000
47. Sehgal I, Baley PA, Thompson TC: Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 56: 3359-3365, 1996
48. Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA, Sawaya R: Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 53: 2208-2211, 1993
49. Jones JL, Glynn P, Walker RA: Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189: 161-168, 1999
50. Hujanen ES, Vaisanen A, Zheng A, Tryggvason K, Turpeenniemi-Hujanen T: Modulation of M(r) 72,000 and M(r) 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int J Cancer 58: 582-586, 1994
51. Nakajima M, Welch DR, Wynn DM, Tsuruo T, Nicolson GL: Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 53: 5802-5807, 1993
52. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S: Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59: 1252-1258, 1999
53. Garbisa S, Pozzatti R, Muschel RJ, Saffiotti U, Ballin M, Goldfarb RH, Khoury G, Liotta LA: Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-Ela. Cancer Res 47: 1523-1528, 1987
54. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087-2091, 1993
55. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516, 2001
56. Yeow KM, Phillips BW, Beaudry PP, Leco KJ, Murphy G, Edwards DR: Expression of MMPs and TIMPs in mammalian cells. Methods Mol Biol 151: 181-189, 2001
57. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002
58. Lauffenburger DA, Horwitz AF: Cell migration: A physically integrated molecular process. Cell 84: 359-369, 1996
59. Genersch E, Schneider DW, Sauer G, Khazaie K, Schuppan D, Lichtner RB: Prevention of EGF-modulated adhesion of tumor cells to matrix proteins by specific EGF receptor inhibition. Int J Cancer 75: 205-209, 1998
60. Zeigler ME, Chi Y, Schmidt T, Varani J: Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J Cell Physiol 180: 271-284, 1999
61. Hartmann G, Weidner KM, Schwarz H, Birchmeier W: The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. J Biol Chem 269: 21936-21939, 1994
62. Klemke RL, Yebra M, Bayna EM, Cheresh DA: Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol 127: 859-866, 1994
63. Howe AK, Juliano RL: Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/mitogen-activated protein kinase cascade. J Biol Chem 273: 27268-27274, 1998
64. Tan JL, Ravid S, Spudich JA: Control of nonmuscle myosins by phosphorylation. Annu Rev Biochem 61: 721-759, 1992
65. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137: 481-492, 1997
66. Ridley AJ: Rho GTPases and cell migration. J Cell Sci 114: 2713-2722, 2001
67. Chrzanowska-Wodnicka M, Burridge K: Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol 133: 1403-1415, 1996
68. Kaibuchi K, Kuroda S, Amano M: Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 68: 459-486, 1999
69. Amano M, Fukata Y, Kaibuchi K: Regulation and functions of Rho-associated kinase. Exp Cell Res 261: 44-51, 2000
70. Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F: Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J Cell Biol 150: 797-806, 2000
71. Tanimura S, Nomura K, Ozaki K, Tsujimoto M, Kondo T, Kohno M: Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. J Biol Chem 277: 28256-28264, 2002
72. Collins P, Webb C: Estrogen hits the surface. Nat Med 5: 1130-1131, 1999
73. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F: Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. Embo J 15: 1292-1300, 1996
74. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ: Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16: 116-127, 2002
75. Bi R, Broutman G, Foy MR, Thompson RF, Baudry M: The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc Natl Acad Sci USA 97: 3602-3607, 2000
76. Rambo CO, Szego CM: Estrogen action at endometrial membranes: alterations in lunfinal surface detectable within seconds. J Cell Biol 97: 679-685, 1983
77. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239-256, 2002
78. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW: Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism. Cancer Res 59: 5475-5478, 1999
79. Reddy KB, Keshamouni VG, Chen YQ: The level of tyrosine kinase activity regulates the expression of p21/WAF1 in cancer cells. Int J Oncol 15: 301-306, 1999
80. Su B, Karin M: Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 8: 402-411, 1996
81. Gulli LF, Palmer KC, Chen YQ, Reddy KB: Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ 7: 173-178, 1996
82. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995
83. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD: programd cell death and the control of cell survival: lessons from the nervous system. Science 262: 695-700, 1993
84. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997
85. Ashkenazi A: Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer 2: 420-430, 2002
86. Eastman A: Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Semin Cancer Biol 6: 45-52, 1995
87. Stadheim TA, Xiao H, Eastman A: Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res 61: 1533-1540, 2001
88. Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE: MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 276: 16484-16490, 2001
89. Holmstrom TH, Schmitz I, Soderstrom TS, Poukkula M, Johnson VL, Chow SC, Krammer PH, Eriksson JE: MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. Embo J 19: 5418-5428, 2000
90. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995
91. Greene LA: Nerve growth factor prevents the death and stimulates the neuronal differentiation of clonal PC12 pheochromocytoma cells in serum-free medium. J Cell Biol 78: 747-755, 1978
92. Buckley S, Driscoll B, Barsky L, Weinberg K, Anderson K, Warburton D: ERK activation protects against DNA damage and apoptosis in hyperoxic rat AEC2. Am J Physiol 277: L159-166, 1999
93. Erhardt P, Schremser EJ, Cooper GM: B-Raf inhibits programd cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19: 5308-5315, 1999
94. Anderson CN, Tolkovsky AM: A role for MAPK/ERK in sympathetic neuron survival: protection against a p53-dependent, JNK-independent induction of apoptosis by cytosine arabinoside. J Neurosci 19: 664-673, 1999
95. Sarker M, Ruiz-Ruiz C, Robledo G, Lopez-Rivas A: Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells. Oncogene 21: 4323-4327, 2002
96. Scheid MP, Duronio V: Dissociation of cytokine-induced phosphorylation of bad and activation of PKB/akt: involvement of MEK upstream of bad phosphorylation. Proc Natl Acad Sci USA 95: 7439-7444, 1998
97. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995
98. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ: Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 182: 821-828, 1995
99. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619-628, 1996